GlassScriptPrepare for your visit
Dennis Dlugos
Neurology with Special Qualifications in Child Neurology · Philadelphia, PA · NPI 1669486551
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$88,301.86
in general payments reported to CMS, 2019-2025 · $13K in 2025
The $13K reported for 2025 was more than what 92% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Who reported paying
General payments only, top 6 by amount.
- Ucb, INC. $17,378.77
- Takeda Pharmaceuticals U.S.A., INC. $13,887.50
- Jazz Pharmaceuticals INC. $9,637.50
- Neurocrine Biosciences, INC. $7,762.24
- Immedica Pharma US, INC. $5,650.00
- Pfizer INC. $5,444.00
Drugs and devices associated with these payments
Fintepla Diacomit Epidiolex
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Dennis Dlugos listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/75115/dennis-dlugos